The Russian government said on Monday that more than 250 Moscow citizens had won the dose of its first Covid-19 vaccine, Sputnik V, in recent days, according to a report.
The vast majority of them are healthy, the coronavirus crisis center told reporters today.
“In the last five days of clinical trials of the vaccine against coronavirus infection, more than 250 citizens of Moscow have been vaccinated in the first seven open centers. Doctors closely monitor the physical condition of vaccinated people. The absolute majority are in optimal physical condition. “75% of the participants do not suffer from any symptoms or diseases,” the crisis center said, according to the Russian news agency.
On Friday, Russian Health Minister Mikhail Murashko told reporters that the first batch of the Russian Covid-19 vaccine would likely be delivered to all regions of the country until September 14, according to the TASS agency.
“The first batches of vaccines have already been sent to check the chain of origin, lately we are checking the delivery formula so that they are aware of them. The first small batches have already been sent to all regions, they will also be sent to the Leningrad region “We will get [the vaccine] among the first. In fact, the first samples of the vaccine will be delivered until Monday,” Murashko said.
This progression comes a week after Russia put the first batch of the Sputnik V vaccine into civilian circulation, the Russian Ministry of Health reported.
The Sputnik V Covid vaccine, developed through the Russian Health Ministry’s Gamaleya Research Institute of Epidemiology and Microbiology, would possibly be allowed to release a batch of its vaccine for civilian purposes, said the institute’s deputy director of studies and associate member of the Russian government. Academy. of Sciences, Denis Logunov previously said, according to a report.
On August 11, Russia became the first country to authorize a Covid-19 vaccine, calling it “Sputnik V” in homage to the world’s first satellite introduced through the Soviet Union. But Western experts have warned that it will not be used to the end. Agreed tests and regulatory measures have been adopted around the world. The vaccine is in phase 3 trials.
The vaccine produced an antibody reaction in all participants in the first trials, according to previous information through the medical journal The Lancet and hailed in Moscow as a reaction to its critics.
The results of the two trials, conducted between June and July of this year and involving 76 participants, showed that one hundred percent of the participants developed antibodies opposed to the novel coronavirus and had no serious side effects, The Lancet reported.
However, an organization of foreign scientists questioned the effects of the Lancet medical journal, stating that some findings are unlikely, Bloomberg reported.
Researchers have raised concerns about the same antibody levels in several study participants who won the experimental vaccine. This and other trends in knowledge raise “several other issues of concern,” according to an open letter written by Temple University professor Enrico Bucci and signed by more than a dozen other scientists.
Download the Mint app and premium items
Sign in to our to save your favorites. It will only be a matter of a moment.